The University of Colorado Cancer Center (UCCC) is organized into 6 research programs, each headed by two co-leaders chosen from consortium institutions. The co-leadership structure was instituted in order to bring more scientifically and geographically comprehensive and complementary oversight and management to the programs. This has also nurtured growth of several internal research foci that have now emerged as potentially new individual research programs. The leadership of the programs is as follows: Robert Sclafani, PhD and Dennis Roop, PhD in Cancer Cell Biology;Al Marcus, PhD and Raj Agarwal, PhD in Cancer Prevention and Control;S. Gail Eckhardt, MD and Wells Messersmith, MD in Developmental Therapeutics;M. Scott Lucia, MD and Heide Ford, PhD in Hormone-related Malignancies;York E. Miller, MD and Xiao- Jing Wang, PhD in Lung, Head &Neck;and James DeGregori, PhD and Joaquin Espinosa, PhD in Molecular Oncology. These twelve exceptional leaders are experts in their respective fields, which include the basic, clinical, and population sciences. Each co-leader brings individual research strengths that complement those of his/her respective co-leader, and both share the management responsibilities of research program leadership. Program leaders serve on the Cancer Center's Governance Committee and on other specific management, operational, and ad hoc committees where their particular talents and expertise is valued and used in programmatic decisions. These UCCC responsibilities include review of shared resource performance and needs, input on recruitments, review of membership, evaluation of seminars, symposia and communications, and participation in planning and evaluation activities including program retreats and genesis of the Strategic Plan. The program co-leaders are responsible for the activities within their own programs that include: 1) educational activities;2) new members and recruitments;3) mentoring of junior faculty;4) fostering collaborative and interdisciplinary research;5) planning and evaluating new and existing shared resources and 6) preparing reports. The educational activities include seminars and symposia including the Center-wide symposia, retreats, poster sessions, training programs, and standard and special courses in the various schools and consortium institutions. All new members have their applications proceed through program leadership to understand the scope of the cancer research and foster new collaborations. Program leaders both mentor young member and also suggest appropriate senior members mentors and steer new members to pilot projects and other grant opportunities.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA046934-26
Application #
8616643
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2014-02-01
Budget End
2015-01-31
Support Year
26
Fiscal Year
2014
Total Cost
$194,919
Indirect Cost
$67,107
Name
University of Colorado Denver
Department
Type
DUNS #
041096314
City
Aurora
State
CO
Country
United States
Zip Code
80045
Harder, Bryan; Tian, Wang; La Clair, James J et al. (2017) Brusatol overcomes chemoresistance through inhibition of protein translation. Mol Carcinog 56:1493-1500
Chen, Yufei; Anastassiadis, Konstantinos; Kranz, Andrea et al. (2017) MLL2, Not MLL1, Plays a Major Role in Sustaining MLL-Rearranged Acute Myeloid Leukemia. Cancer Cell 31:755-770.e6
DeRyckere, Deborah; Lee-Sherick, Alisa B; Huey, Madeline G et al. (2017) UNC2025, a MERTK Small-Molecule Inhibitor, Is Therapeutically Effective Alone and in Combination with Methotrexate in Leukemia Models. Clin Cancer Res 23:1481-1492
Scarborough, Hannah A; Helfrich, Barbara A; Casás-Selves, Matias et al. (2017) AZ1366: An Inhibitor of Tankyrase and the Canonical Wnt Pathway that Limits the Persistence of Non-Small Cell Lung Cancer Cells Following EGFR Inhibition. Clin Cancer Res 23:1531-1541
Neelakantan, Deepika; Zhou, Hengbo; Oliphant, Michael U J et al. (2017) EMT cells increase breast cancer metastasis via paracrine GLI activation in neighbouring tumour cells. Nat Commun 8:15773
Barón, Anna E; Kako, Severine; Feser, William J et al. (2017) Clinical Utility of Chromosomal Aneusomy in Individuals at High Risk of Lung Cancer. J Thorac Oncol 12:1512-1523
Todd, Maria C; Langan, Thomas A; Sclafani, Robert A (2017) Doxycycline-Regulated p16MTS1 Expression Suppresses the Anchorage-Independence and Tumorigenicity of Breast Cancer Cell Lines that Lack Endogenous p16. J Cancer 8:190-198
Brown, Dustin G; Borresen, Erica C; Brown, Regina J et al. (2017) Heat-stabilised rice bran consumption by colorectal cancer survivors modulates stool metabolite profiles and metabolic networks: a randomised controlled trial. Br J Nutr 117:1244-1256
Haverkos, Bradley M; Abbott, Diana; Hamadani, Mehdi et al. (2017) PD-1 blockade for relapsed lymphoma post-allogeneic hematopoietic cell transplant: high response rate but frequent GVHD. Blood 130:221-228
Shearn, Colin T; Saba, Laura M; Roede, James R et al. (2017) Differential carbonylation of proteins in end-stage human fatty and nonfatty NASH. Free Radic Biol Med 113:280-290

Showing the most recent 10 out of 1448 publications